KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Raw Materials (2016 - 2018)

Emergent BioSolutions' Raw Materials history spans 8 years, with the latest figure at $51.8 million for Q4 2018.

  • For Q4 2018, Raw Materials rose 43.49% year-over-year to $51.8 million; the TTM value through Dec 2018 reached $51.8 million, up 43.49%, while the annual FY2018 figure was $51.8 million, 43.49% up from the prior year.
  • Raw Materials reached $51.8 million in Q4 2018 per EBS's latest filing, up from $33.8 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $51.8 million in Q4 2018 to a low of $15.0 million in Q2 2014.
  • Average Raw Materials over 5 years is $27.5 million, with a median of $29.3 million recorded in 2016.
  • Peak YoY movement for Raw Materials: surged 614.81% in 2014, then dropped 7.19% in 2015.
  • A 5-year view of Raw Materials shows it stood at $17.4 million in 2014, then grew by 22.45% to $21.3 million in 2015, then skyrocketed by 44.24% to $30.7 million in 2016, then grew by 17.64% to $36.1 million in 2017, then surged by 43.49% to $51.8 million in 2018.
  • Per Business Quant, the three most recent readings for EBS's Raw Materials are $51.8 million (Q4 2018), $33.8 million (Q3 2018), and $34.4 million (Q2 2018).